What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

Tuesday, XBiotech Inc (NASDAQ:XBIT) announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer.The study examined the Natrunix (anti-interleukin-1alpha) antibody in combina

BenzingaJun 18 13:08 ET

Express News | XBiotech Shares Are Trading Higher After the Company Shared Results From the 1-BETTER Study for Advanced Pancreatic Cancer

BenzingaJun 18 11:49 ET

XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...

XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind Dur

BenzingaJun 18 11:49 ET

XBiotech Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

PDF Version Kaplan-Meier Product Limit Comparison Overall Survival (OS) defined as from time of randomization to death. Natrunix + ON+5FU+LV (n=3) vs Placebo + ON+5FU+LV arms (n=32) w

XBiotechJun 18 00:00 ET

XBiotech | 10-Q: Quarterly report

SEC announcementMay 10 11:29 ET · Announcements

XBiotech Inc.'s (NASDAQ:XBIT) Market Cap up US$57m Last Week, Benefiting Both Retail Investors Who Own 45% as Well as Insiders

Key Insights XBiotech's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the top 7 sharehol

Simply Wall StApr 9 06:00 ET